Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Market Cap	10.46B 70.01B 9.37B 8.64B 7.82B 14.62B 996B 14.86B 103B 41.12B 521B 39.24B 38.4B 1,650B	P/E 2017	-154x	P/E 2018	-708x
Enterprise Value	10.49B 70.21B 9.39B 8.66B 7.84B 14.66B 998B 14.9B 103B 41.24B 523B 39.35B 38.51B 1,655B	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
26/04/21	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI
17/02/20	Veloxis Pharmaceuticals A/S Announces Board Appointments	CI
07/02/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
14/01/20	Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	CI
25/11/19	Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
25/11/19	Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	CI
13/11/19	Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
12/11/19	Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
31/10/19	Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	CI

02/06/21	Scandion Oncology A/S : appoints Johnny Stilou as new CFO	AQ
17/02/20	Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	AQ
29/01/20	Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	AQ
27/01/20	Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	AQ
27/01/20	Veloxis Pharmaceuticals A/S : - Major Shareholder Notifications	AQ

Veloxis Pharmaceuticals A/S Stock

Stocks

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news: Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	13/09/2017
Stacy Wheeler COO	Chief Operating Officer	-	01/03/2016

Director	Title	Age	Since
Keigo Nakatsukasa CHM	Chairman	-	-
Yusuke Hiramatsu BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
ELI LILLY AND COMPANY	+6.63%	+5.13%	+68.86%	+145.20%	1,224B
JOHNSON & JOHNSON	+1.53%	+2.84%	+47.48%	+89.01%	662B
ABBVIE INC.	+1.68%	+1.96%	+29.16%	+109.31%	514B
ROCHE HOLDING AG	+0.26%	+3.38%	+54.41%	+67.47%	388B
MERCK & CO., INC.	+3.83%	-0.62%	+69.01%	+42.32%	361B
NOVARTIS AG	+0.98%	+4.36%	+35.09%	+57.84%	302B
ASTRAZENECA PLC	+3.86%	+5.83%	+8.18%	+32.82%	271B
AMGEN INC.	+1.97%	+3.01%	+57.91%	+76.14%	249B
GILEAD SCIENCES, INC.	+4.03%	+5.36%	+39.76%	+116.14%	205B
Average	+2.01%	+2.33%	+45.54%	+81.81%	417.85B
Weighted average by Cap.	+1.99%	+3.04%	+50.79%	+96.60%

	2017	2018
Net sales	30.17M 202M 27.02M 24.93M 22.56M 42.18M 2.87B 42.86M 297M 119M 1.5B 113M 111M 4.76B	39.49M 264M 35.37M 32.64M 29.53M 55.22M 3.76B 56.12M 389M 155M 1.97B 148M 145M 6.23B
Net income	-9.54M -63.89M -8.55M -7.88M -7.14M -13.34M -909M -13.56M -94.07M -37.53M -476M -35.81M -35.05M -1.51B	-5.28M -35.39M -4.73M -4.37M -3.95M -7.39M -503M -7.51M -52.1M -20.79M -263M -19.83M -19.41M -834M
Net Debt	18.05M 121M 16.17M 14.92M 13.5M 25.24M 1.72B 25.65M 178M 71M 900M 67.75M 66.3M 2.85B	29.38M 197M 26.32M 24.28M 21.97M 41.09M 2.8B 41.75M 290M 116M 1.46B 110M 108M 4.64B